Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Retained Earnings for 10 years, with the latest figure at -$439.5 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 266291.52% year-over-year to -$439.5 million; the trailing twelve-month figure through Mar 2026 stood at -$439.5 million (down 266291.52% YoY), and the FY2025 full-year result was -$462.1 million, up 11.32% from the prior year.
• Retained Earnings for Q1 2026 stood at -$439.5 million, up from -$462.1 million in the prior quarter.
• The five-year high for Retained Earnings was $55000.0 in Q1 2023, with the low at -$720.6 million in Q2 2022.
• Historically, Retained Earnings has averaged -$270.3 million across 5 years, with a median of -$439.5 million in 2026.
• Annual changes were most pronounced in 2022 — Retained Earnings surged 166.67% — and 2024, when it slumped 51225400.0%.
• Kiniksa Pharmaceuticals International's Retained Earnings stood at $44000.0 in 2022, then tumbled by 1086350.0% to -$478.0 million in 2023, then dropped by 9.04% to -$521.1 million in 2024, then climbed by 11.32% to -$462.1 million in 2025, then climbed by 4.89% to -$439.5 million in 2026.
• The last three Retained Earnings figures came in at -$439.5 million (Q1 2026), -$462.1 million (Q4 2025), and -$476.3 million (Q3 2025), per Business Quant data.